Supplied formHeterogeneous animal-tissue-derived peptide and protein extract. No single sequence, formula, molecular weight or small-molecule purity applies. This SKU is Thymalin only; it does not include Thymulin/FTS.
Lead time14–21 days
Representative packaging image · verify the ordered lot
Decision summary
Key benefits
The supported B2B value is for research on animal-derived thymic extract fingerprints, cell-response assays and historical thymic-bioregulator literature
Claims of immune restoration, infection reduction, mortality reduction, anti-ageing, cancer benefit or COVID-19 treatment arise from poorly reported long-term cohorts, small single-centre trials, preclinical work or closely affiliated studies and must not be presented as established benefits of this lot.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
Formula
Identity not settled; confirm on the batch COA
Appearance
Lot-specific lyophilized research material, commonly off-white to white. Appearance or solution clarity cannot establish identity, composition, sterility or suitability.
Purity
Not expressible as a single-compound percentage; release by quantitative content plus validated multi-method compositional fingerprint and safety specifications. · target, verify batch COA
Storage
Follow the lot COA and validated stability protocol for the exact extract. Protect from heat, moisture and repeated temperature cycling. Because this is an animal-derived multicomponent material, stability must monitor fingerprint similarity, total content, degradation and microbial attributes rather than relying on appearance alone.
MOQ
1 kit (10 vials) per SKU
Lead time
14–21 days
Qualification matrix
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Follow the storage condition stated on the batch COA or label from receipt onward.
Research context
What researchers study about Thymalin/Thymulin
Thymalin is described in the literature as a polypeptide complex isolated from calf or bovine thymus, not a single defined peptide. Published work is concentrated within the Khavinson-linked research network and includes cell studies, two small single-centre randomized COVID-19 reports and long-term geroprotector reports with insufficient methods detail in their abstracts for independent causal appraisal. These studies do not define a universal composition or demonstrate equivalence of a new 10 mg research lot. Literature discusses KE, EW and EDP short peptides in relation to Thymalin, but their presence and amount in a supplied batch must be analytically demonstrated. Thymulin/FTS is a separate defined nonapeptide and has been removed from this SKU.
Appropriate work includes raw-material fingerprinting, lot-comparability studies, identification and quantification of peptide components, cell-based immune-signaling assays and evaluation of extraction or degradation variables
Historical immune, ageing, oncology and COVID-19 reports define literature context only; they do not create a drug indication or human-use protocol for this SKU.
Mechanism context
The question the literature is testing
Cell and molecular studies from the principal research network report changes in hematopoietic-cell markers, cytokines and gene-expression models after exposure to Thymalin or selected short peptides. Because the extract is heterogeneous, those findings cannot be assigned to a single active molecule or assumed for an uncharacterized batch. Molecular docking and in vitro cytokine results are hypothesis-generating and do not establish human mechanism, exposure or clinical efficacy.
Evidence map
Research routes and exposure context
Evidence tierHuman clinical researchResearch areaImmune signaling researchRoutes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Published claims of few side effects do not substitute for modern adverse-event collection or product-specific toxicology
The material is not FDA-approved, and FDA warned in 2024 that marketing a Thymalin research product for human conditions, including use in children, constituted unapproved-new-drug and misbranding violations
This RUO extract is not sterile or qualified for injection and no pregnancy, paediatric, autoimmune, transplant or oncology safety conclusion is made.
Interactions reported in the literature
No reliable clinical interaction or synergy matrix is established for this extract with Thymulin, Epitalon, Thymosin Alpha-1, Thymogen, Pinealon, corticosteroids, immunosuppressants, chemotherapy or radiotherapy
Apparent antagonism or synergy based on mechanism is speculative
Research combinations require component characterization and protocol-specific controls.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Batch documentation
Thymalin/Thymulin batch COAs
Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.
Third-party reports, added progressively
Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.
Help reviewing your COA
Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.
On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep
Third-party reports for Thymalin/Thymulin
Reports from Qorix (tjqxgd.com), a third-party analytical laboratory in Tianjin, China: HPLC purity and MS identity of the sample tested.
Laboratory: Third-party laboratoryTests: HPLC purity · MS identity
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Ask for the current packet, not a generic certificate
Require declared bovine species, thymus tissue and country/establishment traceability; veterinary health and TSE/BSE documentation; controlled extraction, clarification and inactivation records; total peptide and protein content; orthogonal SEC, RP-HPLC and LC-MS fingerprints with reference-lot similarity ranges; targeted confirmation of claimed KE, EW or EDP components; residual process chemicals, water, elemental impurities, bioburden, endotoxin and form-specific stability
If sterility is claimed, require a validated sterile process and compendial testing, but this RUO listing makes no sterile-use claim
A white powder, clear reconstitution or nominal 99% HPLC result is not adequate release evidence.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
TY1010 mg10 vials
Other format
Also available as a nasal spray (US stock)
10 mL nasal spray bottle
Besides lyophilized vials, Thymalin/Thymulin is also supplied as a nasal spray solution, shipped from our US stock.
Strengths
10 mg
Bottle sizes
10 mL or 20 mL
Minimum order
10 bottles per strength and bottle size
Ships from
Our US stock
Handling
Plan storage before the parcel arrives
Follow the lot COA and validated stability protocol for the exact extract. Protect from heat, moisture and repeated temperature cycling. Because this is an animal-derived multicomponent material, stability must monitor fingerprint similarity, total content, degradation and microbial attributes rather than relying on appearance alone.
State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
What if my own lab test shows the product is out of specification?+
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
How should material be stored after delivery?+
Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
PMID 14523363 and PMID 12577695 are overlapping 6-8-year geroprotector reports whose abstracts do not provide enough allocation, blinding, attrition or baseline detail for independent causal appraisal. PMID 33575961/PMCID PMC7877506 reports a small single-centre open-label randomized COVID-19 comparison, while PMCID PMC8654498 reports a separate small prospective randomized single-blind severe-COVID comparison; neither provides independent replication or proves equivalence of this lot. PMCID PMC8365293 is a narrative review by the same network. PMCID PMC10488166 combines docking, bioinformatics and in vitro work. PMCID PMC7686446 reports in vitro hematopoietic-cell-marker changes, and PMID 29797130 is a rat sarcoma study. FDA's 2024 warning letter is the primary U.S. regulatory source; the 2011 EMA TSE guidance supplies the relevant quality framework for bovine-derived materials.
01
Peptides of pineal gland and thymus prolong human life
Neuroendocrinology Letters · 2003 · original long-term clinical report (PubMed-indexed as a randomized controlled trial; allocation methods not reported in the abstract)
The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19
International Journal of Molecular Sciences · 2023 · peer-reviewed original research (molecular docking, bioinformatics, and in vitro study)
Why must Thymalin and Thymulin be ordered as separate products?+
Thymalin is a heterogeneous bovine-thymus extract released by a compositional fingerprint; Thymulin/FTS is a defined zinc-dependent nonapeptide. A single-peptide HPLC purity or mass result for Thymulin cannot release Thymalin, and a Thymalin extract fingerprint cannot identify Thymulin. Thymalin's identity is confirmed per lot from the batch COA, and this SKU and COA must state Thymalin only.
What documentation should accompany a Thymalin research lot?+
Require animal species and tissue, country and establishment traceability, veterinary and TSE/BSE risk documentation, extraction and inactivation process summary, total peptide/protein content, orthogonal SEC/RP-HPLC and LC-MS fingerprint comparison, lot-to-lot similarity, water, residual process chemicals, bioburden, endotoxin and stability. A generic purity percentage is not sufficient.
Can a heterogeneous Thymalin extract be described as at least 99% pure?+
No single-compound 99% purity claim is scientifically meaningful for an intentionally multicomponent extract. Report total content and a validated compositional fingerprint with defined acceptance ranges. Any stated HPLC percentage must identify the measured analyte and method rather than imply that the whole extract is one molecule.
